178 related articles for article (PubMed ID: 34413086)
1. Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients.
Lulu AM; Cummings KL; Jeffery ED; Myers PT; Underwood D; Lacy RM; Chianese-Bullock KA; Slingluff CL; Modesitt SC; Engelhard VH
Cancer Immunol Res; 2021 Nov; 9(11):1327-1341. PubMed ID: 34413086
[TBL] [Abstract][Full Text] [Related]
2. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
3. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36798179
[TBL] [Abstract][Full Text] [Related]
4. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
5. MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases.
Mahoney KE; Shabanowitz J; Hunt DF
Mol Cell Proteomics; 2021; 20():100112. PubMed ID: 34129940
[TBL] [Abstract][Full Text] [Related]
6. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.
Zarling AL; Obeng RC; Desch AN; Pinczewski J; Cummings KL; Deacon DH; Conaway M; Slingluff CL; Engelhard VH
Cancer Res; 2014 Dec; 74(23):6784-95. PubMed ID: 25297629
[TBL] [Abstract][Full Text] [Related]
7. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
[TBL] [Abstract][Full Text] [Related]
8. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
Zarling AL; Polefrone JM; Evans AM; Mikesh LM; Shabanowitz J; Lewis ST; Engelhard VH; Hunt DF
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14889-94. PubMed ID: 17001009
[TBL] [Abstract][Full Text] [Related]
9. Tumor Infiltrating Lymphocytes Target HLA-I Phosphopeptides Derived From Cancer Signaling in Colorectal Cancer.
Penny SA; Abelin JG; Malaker SA; Myers PT; Saeed AZ; Steadman LG; Bai DL; Ward ST; Shabanowitz J; Hunt DF; Cobbold M
Front Immunol; 2021; 12():723566. PubMed ID: 34504498
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
[TBL] [Abstract][Full Text] [Related]
11. Generation of Phosphopeptide-Specific T Cell Lines as Tools for Melanoma Immunotherapy.
Obeng RC; Ambakhutwala AL
Methods Mol Biol; 2021; 2265():655-670. PubMed ID: 33704746
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.
Li Y; Depontieu FR; Sidney J; Salay TM; Engelhard VH; Hunt DF; Sette A; Topalian SL; Mariuzza RA
J Mol Biol; 2010 Jun; 399(4):596-603. PubMed ID: 20417641
[TBL] [Abstract][Full Text] [Related]
13. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.
Cobbold M; De La Peña H; Norris A; Polefrone JM; Qian J; English AM; Cummings KL; Penny S; Turner JE; Cottine J; Abelin JG; Malaker SA; Zarling AL; Huang HW; Goodyear O; Freeman SD; Shabanowitz J; Pratt G; Craddock C; Williams ME; Hunt DF; Engelhard VH
Sci Transl Med; 2013 Sep; 5(203):203ra125. PubMed ID: 24048523
[TBL] [Abstract][Full Text] [Related]
14. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.
Frøsig TM
Dan Med J; 2015 Aug; 62(8):B5144. PubMed ID: 26239596
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients.
Ingersoll SB; Stoltzfus GP; Merchant MH; Ahmad S; Edwards CR; Ahmed A; Oyer JL; Finkler NJ; Holloway RW; Edwards JR
Cytotherapy; 2012 Jul; 14(6):716-23. PubMed ID: 22409787
[TBL] [Abstract][Full Text] [Related]
17. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
18. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
19. The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.
Mohammed F; Stones DH; Zarling AL; Willcox CR; Shabanowitz J; Cummings KL; Hunt DF; Cobbold M; Engelhard VH; Willcox BE
Oncotarget; 2017 Aug; 8(33):54160-54172. PubMed ID: 28903331
[TBL] [Abstract][Full Text] [Related]
20. Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry.
Abelin JG; Trantham PD; Penny SA; Patterson AM; Ward ST; Hildebrand WH; Cobbold M; Bai DL; Shabanowitz J; Hunt DF
Nat Protoc; 2015 Sep; 10(9):1308-18. PubMed ID: 26247297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
